FindTrial
Sign In

Cardiotoxicity induced by tyrosine kinase inhibitors in cancer patients

A Prospective Observational study to assess the cardiotoxicity induced by tyrosine kinase inhibitors in a tertiary care hospital

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011131
Enrollment
80
Registered
2018-01-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Cancer Patients

Interventions

None listed

Sponsors

Koilagundla Niranjan
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Age 18 to 60 years of either gender 2 Subjects who will be undergoing therapy with tyrosine kinase inhibitors for various cancers 3 those who are willing to give informed consent 4 those who are willing to follow study related procedures

Exclusion criteria

Exclusion criteria: 1 History of cardiovascular diseases 2 history of intake of other concomitant cardiotoxic drugs 3 Pregnant and lactating females 4 History of secondary or previous history of any other malignancies

Design outcomes

Primary

MeasureTime frame
Percentage of subjects with TKI induced cardiotoxicityTimepoint: 0,1,3,6 months—

Secondary

MeasureTime frame
Correlation of patient and disease related factorsTimepoint: 6 months;Number of subjects with specific adverse eventsTimepoint: 0,1,3,6 months—

Countries

India

Contacts

Public ContactKoilagundla Niranjan

Nizams Institute of Medical Sciences

ushapingali@yahoo.com9849574143

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026